Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)

Clinical Cancer Research

Volumn 21, Issue 23, 2015, Pages 5294-5304

  Sinicrope, Frank A ^a   Mahoney, Michelle R ^a   Yoon, Harry H ^a   Smyrk, Thomas C ^a   Thibodeau, Stephen N ^a   Goldberg, Richard M ^b   Nelson, Garth D ^a   Sargent, Daniel J ^a   Alberts, Steven R ^a  

^a MAYO CLINIC CANCER CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MISMATCH REPAIR PROTEIN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; TUMOR MARKER; ANTINEOPLASTIC AGENT; RAS PROTEIN;

ADULT; AGED; ARTICLE; BRAF GENE; CANCER PROGNOSIS; CANCER STAGING; CECUM; CODON; COLON CARCINOMA; CONTROLLED STUDY; EXON; FEMALE; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; SIGMOID; TRANSVERSE COLON; TUMOR LOCALIZATION; ADJUVANT CHEMOTHERAPY; CANCER GRADING; COLONIC NEOPLASMS; GENETICS; METASTASIS; MIDDLE AGED; MISMATCH REPAIR; MORTALITY; MULTICENTER STUDY (TOPIC); MUTATION; OUTCOME ASSESSMENT; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; COLONIC NEOPLASMS; DNA MISMATCH REPAIR; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MUTATION; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; YOUNG ADULT;

EID: 84938347734     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0527     Document Type: Article

References (40)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Mouradov D, Sloggett C, Jorissen RN, Love CG, Li S, Burgess AW, et al. Colorectal cancer cell lines are representative models of themain molecular subtypes of primary cancer. Cancer Res 2014;74:3238-47.
3. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934.
4. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.
5. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38:787-93.
6. Domingo E, Laiho P,Ollikainen M, PintoM,Wang L, French AJ, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004;41:664-8.
7. Sweetser S, Smyrk TC, Sinicrope FA. Serrated colon polyps as precursors to colorectal cancer. Clin Gastroenterol Hepatol 2013;11:760-7; quiz e54-5.
8. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al.Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
9. Yaeger R, Cercek A, Chou JF, Sylvester BE, Kemeny NE, Hechtman JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer 2014; 120:2316-24.
10. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011;117:4623-32.
11. Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C, Budinska E, et al. Distal and proximal colon cancers differ in terms of molecular, pathological and clinical features. Ann Surg Oncol 2014;25:1995-2001.
12. Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H. Comparison of 17,641 patients with right-and left-sided colon cancer: Differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 2010;53:57-64.
13. Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is there a difference in survival between right-versus left-sided colon cancers? Ann Surg Oncol 2008;15:2388-94.
14. Weiss JM, Pfau PR, O'Connor ES, King J, LoConte N, Kennedy G, et al. Mortality by stage for right-versus left-sided colon cancer: Analysis of surveillance, epidemiology, and end results-Medicare data. J Clin Oncol 2011;29:4401-9.
15. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. JAMA 2012;307:1383-93.
16. Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOXbased adjuvant chemotherapy. J Clin Oncol 2013;31:3664-72.
17. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New Engl J Med 2008;359:1757-65.
18. Angulo B, Garcia-Garcia E, Martinez R, Suarez-Gauthier A, Conde E, Hidalgo M, et al. A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: A morphologybased approach in colorectal carcinoma. J Mol Diagn 2010;12:292-9.
19. Sinicrope FA, Rego RL, Garrity-Park MM, Foster NR, Sargent DJ, Goldberg RM, et al. Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability. Int J Cancer 2007;120:1232-8.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assn 1958;53:457-81.
21. Cox DR. Regression models and life-tables. J Roy Statist Soc 1972; 34:187-220.
22. Team R. A language and environment for statistical computing. Vienna, Austria: R: Foundation for Statistical Computing; 2011.
23. Sinicrope FA, Sargent DJ. Molecular pathways: Microsatellite instability in colorectal cancer: Prognostic, predictive, and therapeutic implications.Clin Cancer Res 2012;18:1506-12.
24. Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): An open-label, randomised phase 3 trial. Lancet Oncol 2014;15:862-73.
25. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008;135:1079-99.
26. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012;61:847-54.
27. Popovici V, Budinska E, Bosman FT, Tejpar S, Roth AD, Delorenzi M. Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer. BMC Cancer 2013;13:439.
28. Hayashi H, Takahashi R,Nishi T, SakamotoM, Benno Y. Molecular analysis of jejunal, ileal, caecal and recto-sigmoidal human colonic microbiota using 16S rRNA gene libraries and terminal restriction fragment length polymorphism. J Med Microbiol 2005;54:1093-101.
29. Surana NK, Kasper DL. Deciphering the tete-a-tete between themicrobiota and the immune system. J Clin Invest 2014;124:4197-203.
30. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466-74.
31. Farina-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010;21:2396-402.
32. Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, et al. Predictive and prognostic roles of BRAFmutation in stage III colon cancer: Results from intergroup trial CALGB 89803. Clin Cancer Res 2012;18:890-900.
33. Gavin PG, Colangelo LH, Fumagalli D, Tanaka N, Remillard MY, Yothers G, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: An assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 2012;18:6531-41.
34. Popovici V, Budinska E, Tejpar S, Weinrich S, Estrella H, Hodgson G, et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol 2012;30:1288-95.
35. Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, et al. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 2014;20:3033-43.
36. Blons H, Emile JF, Le Malicot K, Julie C, Zaanan A, Tabernero J, et al. Prognostic value of KRAS mutations in stage III colon cancer: Post hoc analysis of the PETACC8 phase III trial dataset. Ann Oncol 2014;25: 2378-85.
37. Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res 2012;18:4753-63.
38. Klingbiel D, Saridaki Z, Roth AD, Bosman FT, Delorenzi M, Tejpar S. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation tomicrosatellite status: Results of the PETACC-3 trial. Ann Oncol 2015;26:126-32.
39. Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology 2015;148:88-99.
40. Flejou JF, Andre T, Chibaudel B, Scriva A,Hickish T, Tabemero J, et al. Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study. J Clin Oncol 2013;31:3524.